What does Harrow, Inc. do?
Harrow, Inc. (Nasdaq: HROW) is a focused ophthalmic pharmaceutical company. It sells FDA-approved branded medicines, operates an ophthalmology compounding business, and develops or licenses products for conditions across the front and back of the eye. The portfolio spans dry eye, ocular anesthesia, surgical care, retinal disease, infection, inflammation, and rare ocular-surface conditions. Its access mission is operationally relevant because reimbursement, patient cost, supply reliability, and practice workflow determine adoption. The company's official product portfolio shows how broad the platform has become.
Which businesses and products define the portfolio?
Why does an ophthalmology-only platform matter?
Harrow's specialization creates a common commercial call point: ophthalmologists, optometrists, retina specialists, and surgery centers. One relationship can support products used before, during, and after procedures or across chronic treatment. That can improve selling efficiency, but it concentrates Harrow in one therapeutic ecosystem. With limited glaucoma exposure and substantially all revenue in the United States, diversification comes from products and care settings rather than geography.
How does Harrow make money?
The model has two economic engines. The Branded segment sells prescription and non-prescription products, largely through third-party distributors, and can also receive licensing or royalty revenue. ImprimisRx earns product revenue from compounded formulations dispensed for patient-specific prescriptions or supplied for in-office use. The mix matters because branded products generally offer higher gross margins and more operating leverage, while compounding provides recurring practice relationships, direct customer insight, and a channel for products that address unmet formulation needs.
Which revenue streams drove FY2025?
| Revenue source | FY2025 revenue | Share of FY2025 | Economic role |
|---|---|---|---|
| VEVYE | $88.7M | 33% | Largest individual product; dry-eye growth and gross-to-net discipline are central. |
| IHEEZO | $81.3M | 30% | Physician-administered ocular anesthetic tied to procedural use and reimbursement. |
| ImprimisRx | $76.5M | 28% | Compounding revenue and a relationship channel into eyecare practices. |
| Other branded products | $25.3M | 9% | Portfolio breadth across anti-infective, anti-inflammatory, ocular-surface, and surgical products. |
FY2025 revenue reached $272.3 million, up 36% from FY2024. Branded revenue was $195.8 million, or 72% of the total, while ImprimisRx contributed $76.5 million, or 28%. That is a major structural shift from FY2023, when branded revenue represented 39% and compounding represented 61%. The FY2025 Form 10-K documents this transition from a compounding-led company toward a branded ophthalmic platform.
What changed in the latest revenue mix?
What turning points created today's Harrow?
Harrow evolved from a restructured public entity into an ophthalmic compounder and then an acquirer, licensor, and developer of FDA-approved products. Each step added commercial infrastructure while increasing capital needs, debt, amortization, reimbursement exposure, and execution complexity.
Which decisions still shape the strategy?
-
2012
A reorganization led by Mark Baum and Andrew Boll created Imprimis Pharmaceuticals. The enduring effect was an entrepreneurial, acquisition-oriented operating model.
-
2014
ImprimisRx began serving ophthalmic practices with compounded formulations. That prescriber network became the company's original distribution and market-intelligence advantage.
-
2018
The Harrow Health name reflected a strategy broader than compounding and a growing focus on branded ophthalmic assets.
-
2021–2023
Licensing and launches around IHEEZO, followed by the $130.0M acquisition of five Novartis ophthalmic products, materially expanded the branded platform and balance-sheet intensity.
-
2023
Harrow acquired VEVYE rights and a Santen portfolio, then shortened its name to Harrow, Inc. The company became a multi-product commercial ophthalmology business rather than a pharmacy-centered story.
-
2025
Project Beagle began shifting selected patients from compounded products toward Harrow-owned FDA-approved alternatives; the remaining interests in Melt Pharmaceuticals were acquired to bring MELT-300 under full control.
-
2026
Harrow re-launched VERKAZIA and commercially launched BYOOVIZ on July 1, extending its specialty and retina franchises while Q1 results exposed the cost of scaling ahead of revenue.
What does Harrow's latest quarter show?
The quarter ended March 31, 2026 was a reset after a strong FY2025: revenue fell, gross margin compressed, expenses increased, and cash flow turned negative. Management attributed the decline mainly to VEVYE gross-to-net reductions tied to coverage and cash-pay access, plus lower compounded-product sales. The latest Q1 2026 Form 10-Q is therefore more informative about near-term execution risk than the record fourth quarter that preceded it.
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Revenue | $44.2M | $47.8M | Down 8%; VEVYE deductions and compounding weakness offset other branded growth. |
| Gross profit / margin | $27.0M / 61% | $32.3M / 68% | Lower product mix, VEVYE gross-to-net deductions, and weak facility utilization reduced economics. |
| SG&A | $43.2M | $40.5M | Commercial headcount and launch infrastructure continued to expand. |
| R&D | $5.9M | $3.0M | NDA-enabling work for the Melt/G-MELT program increased development spending. |
| Operating loss | $(22.1)M | $(11.2)M | The cost base was built for a larger revenue run rate than the quarter delivered. |
| Net loss / diluted EPS | $(27.6)M / $(0.74) | $(17.8)M / $(0.50) | Interest expense and operating losses kept GAAP earnings deeply negative. |
Why did revenue and margin weaken?
VEVYE generated $20.9 million in Q1 2026, slightly below $21.5 million a year earlier, because coverage wins and the $59-or-less cash-pay approach increased deductions from gross sales. IHEEZO revenue fell to $1.9 million from $5.2 million, while other branded products rose to $7.8 million from $1.0 million. ImprimisRx declined to $13.5 million from $20.1 million. Branded gross margin was 64.3%, down from 70.6%; compounding gross margin was 54.0%, down from 63.4%.
What do cash flow and working capital say?
Operating cash flow was $(9.0) million in Q1 2026 versus $19.7 million in Q1 2025. Cash increased to $94.6 million, but mainly because financing activities supplied $48.9 million after the company issued another $50.0 million of 8.625% senior notes due 2030. Accounts receivable remained high at $101.3 million. The company's Q1 2026 stockholder letter frames the quarter as a temporary step in a traditional seasonal build, but the cash-flow evidence makes the next two quarters important validation points.
Branded scale, reimbursement, and distribution define Harrow's moat
Harrow's advantage is a system: a specialized sales force, prescriber relationships, FDA-approved products, practice-level knowledge from ImprimisRx, and shared market-access and distribution capabilities. Patents add protection—IHEEZO has listed coverage into 2039 and VEVYE as late as 2039—but durability still depends on reimbursement and clinician adoption.
Where is the competitive advantage strongest?
The strongest resource is customer access. ImprimisRx serves more than 10,000 U.S. prescribers and institutions, and the company is using Project Beagle to move selected patients from compounded formulations toward Harrow-owned FDA-approved products. This can increase revenue quality and regulatory clarity while preserving practice relationships. The July 2026 commercial launch of BYOOVIZ shows the same platform logic in retina: Harrow can sell a therapeutic biosimilar alongside IHEEZO and TRIESENCE to the same specialist customer base.
Which constraints limit the moat?
Harrow does not manufacture its branded medicines; it depends on third-party partners across the United States, Europe, and Taiwan. Three suppliers represented 69% of manufacturing-supply purchases in Q1 2026. Reimbursement is equally important. IHEEZO's temporary Medicare pass-through period was expected to expire on March 31, 2026, and VEVYE economics were already affected by rebates, coverage terms, and cash-pay access. A product can have clinical differentiation and still generate disappointing net revenue if payer deductions, coding, practice economics, or supply availability are unfavorable.
Who competes with Harrow, and where is it positioned?
Harrow faces large branded ophthalmic franchises, generic manufacturers, biosimilar developers, specialty pharmacies, and 503A/503B compounders with greater research, manufacturing, sales, and payer resources. Its counter-positioning is narrower focus: overlooked, supply-constrained, underpromoted, or workflow-specific assets sold through an existing specialist infrastructure.
Which competitive fronts matter most?
| Market | Harrow position | Main alternatives | Decision factor |
|---|---|---|---|
| Dry eye | VEVYE, a water-free cyclosporine solution | Other branded immunomodulators, anti-inflammatory products, generic cyclosporine, and lubricants | Tolerability, onset, formulary access, patient cost, and persistence |
| Ocular anesthesia | IHEEZO for ocular surface anesthesia | Generic topical anesthetics and established procedural protocols | Reimbursement, workflow fit, comfort, and physician habit |
| Retina biologics | BYOOVIZ now; OPUVIZ planned later | Reference anti-VEGF biologics and multiple biosimilars | Interchangeability, economics, supply continuity, and practice support |
| Surgical inflammation | TRIESENCE, ILEVRO, BYQLOVI, and other portfolio products | Generic steroids, NSAIDs, compounded alternatives, and bundled protocols | Label breadth, reimbursement, dosing burden, and surgical efficiency |
| Compounding | Two New Jersey facilities and an ophthalmology-only formulary | Local pharmacies, national outsourcing facilities, and FDA-approved substitutes | Quality, availability, state reach, price, and customization |
Harrow is not dominant by pharmaceutical scale. Its relevance comes from assembling a dense ophthalmic catalog around one commercial channel, creating more cross-selling potential than a single-asset biotech. Larger competitors can still spend more, negotiate better terms, or launch substitutes that compress economics.
How financially strong is Harrow?
FY2025 demonstrated operating profit and cash generation, but Q1 2026 showed that financial strength is not yet stable. The key question is whether revenue can consistently cover a large SG&A base, interest expense, product-right amortization, and pipeline investment.
What changed from FY2023 through FY2025?
| Metric | FY2025 | FY2024 | Research implication |
|---|---|---|---|
| Revenue | $272.3M | $199.6M | 36% growth confirms strong product commercialization. |
| Gross profit | $204.4M | $150.4M | Calculated consolidated gross margin was about 75.1% in FY2025. |
| Operating income | $30.5M | $8.8M | Calculated operating margin improved to about 11.2%. |
| Net loss | $(5.1)M | $(17.5)M | Interest, debt-extinguishment cost, and taxes kept net income negative. |
| Operating cash flow | $43.9M | $(22.2)M | A major improvement, but working-capital timing makes quarterly conversion volatile. |
How does debt alter financial flexibility?
At March 31, 2026, total assets were $419.5 million, current assets were $226.4 million, current liabilities were $91.4 million, and stockholders' equity had fallen to $28.4 million. The current ratio was therefore about 2.5 times, indicating near-term liquidity, but leverage is substantial relative to book equity. The company also had a $40.0 million revolving line, plus a $20.0 million uncommitted expansion option, with no borrowings at quarter-end. Liquidity supports launches, but debt service raises the minimum revenue and margin level needed for equity value creation.
Who owns Harrow stock, and why does governance matter?
Harrow has one common share class and no disclosed dual-class structure, so economic ownership and voting influence are broadly aligned. Founder, Chairman, and CEO Mark Baum is a meaningful stockholder, and officers and directors collectively own a material stake. The latest 2026 proxy statement provides the clearest official ownership snapshot.
What does the investor base signal?
| Holder or group | Beneficial shares | Ownership | Why it matters |
|---|---|---|---|
| Opaleye and related persons | 3,681,428 | 9.88% | A concentrated healthcare-oriented holder can exert more engagement than a passive index fund. |
| Private Capital Management | 3,630,496 | 9.74% | Another large block increases the importance of capital allocation and execution credibility. |
| Mark L. Baum | 3,663,630 | 9.65% | Founder-level ownership aligns incentives but combines with the CEO-chair role to concentrate leadership influence. |
| BlackRock | 2,220,538 | 5.96% | Institutional ownership broadens governance scrutiny and liquidity. |
| Directors and executives as a group | 4,770,347 | 12.80% | Meaningful insider exposure ties management wealth to long-term stock performance. |
Ownership data is as of April 21, 2026, but the proxy notes that several institutional positions were based on older Schedule 13G filings and may not reflect current holdings.
How are incentives and oversight structured?
Baum serves as both CEO and board chair, while Perry Sternberg serves as lead independent director. The 2025 annual bonus framework included revenue, adjusted EBITDA, selected product revenue, and refinancing activity; those metrics encourage commercial growth and financing execution. Equity awards further align management with stock performance, but researchers should distinguish durable operating progress from incentives tied to revenue growth or share price alone. Related-party history around Melt also makes independent oversight and transaction process important governance topics.
Why does Harrow matter for valuation?
Harrow is a useful DCF case because revenue growth, accounting profit, and cash flow can diverge. Acquired rights create amortization; distributor sales create receivables and rebates; launches create expense before revenue matures; and debt creates fixed interest. Valuation should separate product-level revenue curves from margins and explicitly model working capital, royalties, development spending, and debt.
Which drivers belong in a DCF?
Terminal value is sensitive to patent life, competition, reimbursement, and portfolio replenishment. MELT-300 and newly launched products should be probability-adjusted rather than valued at full steady-state potential. Harrow's smaller scale, leverage, U.S. concentration, and unproven repeatable free cash flow also support a higher risk assessment than a diversified pharmaceutical company.
What opportunities and risks could change the story?
The opportunity is to convert a broad portfolio into a high-margin specialist platform; the risk is that commercial spending, payer deductions, supply constraints, and debt grow faster than net revenue. Harrow's June 2026 VERKAZIA re-launch and July 2026 BYOOVIZ launch illustrate the expansion opportunity, while the Q1 results show how costly it is to build several franchises simultaneously.
Which growth initiatives matter most?
What could derail execution?
| Risk | Official signal | Financial line affected | What to monitor |
|---|---|---|---|
| Reimbursement and gross-to-net pressure | VEVYE deductions increased in Q1 2026; IHEEZO pass-through timing changed after March 2026. | Net revenue, gross margin, receivables, rebate accruals | Net price per prescription or unit, coverage wins, payer mix, and cash-pay economics |
| Customer concentration | Three customers represented 95% of consolidated receivables at March 31, 2026. | Working capital and cash conversion | Receivable days, collection timing, distributor inventory, and chargebacks |
| Supply and manufacturing dependence | Branded products are externally manufactured; three suppliers represented 69% of Q1 2026 supply purchases. | Revenue, inventory, cost of sales | Back orders, alternate sites, minimum commitments, and launch inventory |
| Compounding regulation and quality | The company cites ongoing FDA communications regarding its New Jersey outsourcing facility. | Compounding revenue, remediation cost, utilization | Inspection outcomes, state reach, remediation spending, and formulary reductions |
| Leverage and funding | $292.1M of notes payable at March 31, 2026 and $5.5M of Q1 interest expense. | Free cash flow, refinancing risk, equity value | Interest coverage, revolver use, debt maturity planning, and acquisition discipline |
| Pipeline and launch execution | MELT-300 still requires additional studies, an NDA, FDA review, and commercialization. | R&D, milestone payments, terminal value | Study completion, submission timing, approval, coding, reimbursement, and adoption |
What is the key takeaway from Harrow analysis?
Harrow built a pure-play ophthalmology platform from a compounding base, then used acquisitions, licensing, and specialist distribution to create branded scale. FY2025 showed rapid growth, operating profit, and positive operating cash flow. Q1 2026 showed the other side: gross-to-net pressure, mix, weak utilization, commercial investment, R&D, and interest can overwhelm revenue.
For a student or MBA reader, Harrow is a case study in focused diversification, channel leverage, reimbursement economics, and acquisition-led transformation. For a researcher or investor, the next questions are operational: product-level net sales, branded and compounding margins, SG&A leverage, working-capital conversion, debt service, and regulatory milestones. Those variables—not a single quarter's headline revenue—will determine whether Harrow becomes a durable specialist pharmaceutical platform or remains a high-growth business with fragile cash economics.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support


